S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
OTCMKTS:GNBT

Generex Biotechnology - GNBT Stock Forecast, Price & News

$0.0010
0.00 (0.00%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range
N/A
52-Week Range
$0.00
$0.24
Volume
24,889 shs
Average Volume
74,657 shs
Market Capitalization
$122,058.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GNBT stock logo

About Generex Biotechnology (OTCMKTS:GNBT) Stock

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

Receive GNBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generex Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

GNBT Stock News Headlines

See More Headlines
Receive GNBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generex Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

GNBT Company Calendar

Today
8/16/2022
Fiscal Year End
7/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GNBT
Employees
15
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.66 million

Miscellaneous

Free Float
79,094,000
Market Cap
$122,058.00
Optionable
Not Optionable
Beta
-0.32

Key Executives

  • Mr. Joseph Moscato (Age 58)
    CEO, Pres & Chairman
    Comp: $623.08k
  • Mr. Mark Corrao (Age 64)
    CFO & Treasurer
    Comp: $10k
  • Mr. Terry R. Thompson (Age 64)
    Chief Operating Officer
    Comp: $566.44k
  • Mr. Andrew Ro (Age 51)
    Chief Investment Officer & Director
    Comp: $18.88k
  • Mr. Anthony S. Crisci CPA (Age 51)
    Esq., Chief Legal Officer & Chief Admin. Officer
    Comp: $424.83k
  • Mr. Anthony J. Dolisi (Age 57)
    Chief Commercial Officer
  • Dr. Jason Bradley Terrell (Age 42)
    Chief Scientific Officer & Chief Medical Officer
  • Ms. Michelle Starr
    Chief Marketing Officer
  • Mr. Richard D. Purcell (Age 61)
    Exec. VP of Research & Drug Devel.













GNBT Stock - Frequently Asked Questions

How have GNBT shares performed in 2022?

Generex Biotechnology's stock was trading at $0.0619 at the beginning of 2022. Since then, GNBT shares have decreased by 98.4% and is now trading at $0.0010.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Generex Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generex Biotechnology investors own include (UNISQ) (UNISQ), Amgen (AMGN), Novavax (NVAX), VBI Vaccines (VBIV), iBio (IBIO), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Gilead Sciences (GILD) and Quest Diagnostics (DGX).

What is Generex Biotechnology's stock symbol?

Generex Biotechnology trades on the OTCMKTS under the ticker symbol "GNBT."

How do I buy shares of Generex Biotechnology?

Shares of GNBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Generex Biotechnology's stock price today?

One share of GNBT stock can currently be purchased for approximately $0.00.

How much money does Generex Biotechnology make?

Generex Biotechnology (OTCMKTS:GNBT) has a market capitalization of $122,058.00 and generates $2.66 million in revenue each year.

How can I contact Generex Biotechnology?

Generex Biotechnology's mailing address is 10102 USA TODAY WAY, MIRAMAR FL, 33025. The official website for the company is www.generex.com. The company can be reached via phone at (416) 364-2551, via email at investor@generex.com, or via fax at 64-7547-7104.

This page (OTCMKTS:GNBT) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.